Regeneron scratches NGF inhibitor and cat allergy therapy from pipeline

03 Nov 2022
www.fiercebiotech.com
AntibodyCollaborate
Like many other companies, Regeneron has axed programs from its pipeline, including a cat allergy drug and an NGF inhibitor for chronic pain.
The cat’s out of the bag: RRegeneronis leaving two drugs behind, including an NGF inhibitor targeting chronic NGFn and a cat allchronic pain.
The culls were announced NRegenerona third-quarter financial update, burrowed NGFp among third-quarterchronic painsults, cat allergyded a revenue decline of 19% and 11% revenue growth when compared to the third quarter of 2021.
The Big Pharma has axed fasinumab, its Teva- and Mitsubishi Tanabe Pharma-partnered NGF inhibitor. The investigational monoclonal antibody was invented by Regeneron in hopes of addressing chronic pain, specifically for patients with osteoarthritis of the knee or hip.
The drug has an embattlefasinumab, including a 20MitsubishilTanabe Pharmae FDA on a NGFa-partnered phase 2b trial in patients with chronic back pain and osRegenerontis of the knee or hip. chronic painsked the partners to amend the stosteoarthritis of the kneeof a joint disease was reported in a patient receiving a high-dose of fasinumab.
The NGF inhibitor class as a whole has had its share of trouble. In 2011, tFDAFDA put the class on clinical hold over evidence linkchronic back painjointosteoarthritisher adverse events, though the stay was lifted a year later.joint diseasefasinumab
In fNGF 2021, Eli Lilly and Pfizer called time on their osteoarthritis NGF inhFDAtor known as tanezumab. In April 2021, after an FDA advisory committee voted against the drug, Teva CEO Kåre Schultz told investors that the vote against it was “definitely a negative for the product class,” adding that nonessential fasinumab costs were on hold pending a decision on whether to file for approval.
Regeneron recoElizLilly4 milPfizern deferred income in tosteoarthritiseNGFelated to previouslytanezumab upfront payments and deveFDAment milestones for fasinumab, Bob Landry, eTevative vice president and chief financial officer, said during a Nov. 3 earnings call.fasinumab
Regenerond drug tossed from Regeneron’s pipeline was REGN1908-1909, a multi-antibody therapy for cat-allergic asthmatic patients. The drug, which made ifasinumab phase 3 trials, won’t be pawned off to another industry player but instead discontinued fully due to futility, according to the company release.
The Big Pharma’s pipeline stRegenerondes about 35 proREGN1908-1909es, Leonard Schleifer, M.D., Phcat-allergic asthmatict and CEO of Regeneron, said on the earnings call, adding that the company continues to focus on investing on internal R&D capabilities and exploring potential collaborations.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.